{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:44:18Z","timestamp":1767145458536,"version":"build-2238731810"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejphar.2019.172521","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T19:38:43Z","timestamp":1562096323000},"page":"172521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice"],"prefix":"10.1016","volume":"859","author":[{"given":"Satoko","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sou","family":"Sugitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritaka","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.172521_bib1","doi-asserted-by":"crossref","first-page":"R1449","DOI":"10.1152\/ajpregu.2000.279.4.R1449","article-title":"Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms","volume":"279","author":"Balkan","year":"2000","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2019.172521_bib2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation. Results from short-term pharmacokinetic and 12-week dose-ranging studies","volume":"39","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2019.172521_bib3","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00125-016-3992-6","article-title":"Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials","volume":"59","author":"DeFronzo","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2019.172521_bib4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2019.172521_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.coph.2013.08.013","article-title":"Molecular mechanisms of incretin hormone secretion","volume":"13","author":"Ezcurra","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172521_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1471-4159.2011.07563.x","article-title":"Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats","volume":"121","author":"Fujiwara","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2019.172521_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/29.3.6787113","article-title":"Immunohistochemical localization of dipeptidyl aminopeptidase IV in rat kidney, liver, and salivary glands","volume":"29","author":"Fukasawa","year":"1981","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ejphar.2019.172521_bib8","first-page":"130","article-title":"The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation","volume":"64","author":"Furuta","year":"2014","journal-title":"Drug Res."},{"key":"10.1016\/j.ejphar.2019.172521_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13318-013-0119-z","article-title":"Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs","volume":"38","author":"Furuta","year":"2013","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2019.172521_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/laban1005-39","article-title":"A rapid, simple, and humane method for submandibular bleeding of mice using a lancet","volume":"34","author":"Golde","year":"2005","journal-title":"Lab. Anim."},{"key":"10.1016\/j.ejphar.2019.172521_bib11","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7\u201336)amide is transformed to glucagon-like peptide-1-(9 \u201336)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2019.172521_bib12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2019.172521_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0026-0495(98)90027-0","article-title":"Nongenetic mouse models of non-insulin-dependent diabetes mellitus","volume":"47","author":"Luo","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172521_bib14","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/00970002042006005","article-title":"A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals","volume":"42","author":"Martinez","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172521_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.peptides.2017.12.020","article-title":"Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion","volume":"100","author":"McKillop","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2019.172521_bib16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejphar.2019.172521_bib17","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic \u00df-cell mass and function in a rodent model of type 2 diabetes","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2019.172521_bib18","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejphar.2019.172521_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2016.10.007","article-title":"Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis","volume":"25","author":"Mulvihill","year":"2017","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejphar.2019.172521_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.metabol.2013.01.010","article-title":"Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet","volume":"62","author":"Nakaya","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2019.172521_bib21","doi-asserted-by":"crossref","first-page":"E376","DOI":"10.1152\/ajpendo.00565.2012","article-title":"Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways","volume":"305","author":"Nishizawa","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2019.172521_bib22","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.2337\/db14-0052","article-title":"Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors","volume":"63","author":"Omar","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2019.172521_bib23","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2019.172521_bib24","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cmet.2014.04.005","article-title":"The role of \u03b2 cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs","volume":"19","author":"Smith","year":"2014","journal-title":"Cell Metabol."},{"issue":"2","key":"10.1016\/j.ejphar.2019.172521_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/dci15-0013","article-title":"Mechanism of metformin: a tale of two sites","volume":"39","author":"Song","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2019.172521_bib26","doi-asserted-by":"crossref","first-page":"E1076","DOI":"10.1152\/ajpendo.00479.2010","article-title":"Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents","volume":"299","author":"Tatarkiewicz","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2019.172521_bib27","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/en.2006-0153","article-title":"Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats","volume":"148","author":"Vahl","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2019.172521_bib28","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1210\/en.2011-0286","article-title":"Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice","volume":"152","author":"Waget","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2019.172521_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2016.05.011","article-title":"Sensory neurons that detect stretch and nutrients in the digestive system","volume":"166","author":"Williams","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2019.172521_bib30","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/db11-1701","article-title":"The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes","volume":"61","author":"Woerle","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2019.172521_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jdiacomp.2014.12.010","article-title":"Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients","volume":"29","author":"Yabe","year":"2015","journal-title":"J. Diabet. Complicat."}],"updated-by":[{"DOI":"10.1016\/j.ejphar.2019.172633","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000}}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429991930473X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429991930473X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:31:02Z","timestamp":1757975462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429991930473X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":31,"alternative-id":["S001429991930473X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172521","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172521"}}